ArticleJournal of thoracic disease2026
The combination of pralsetinib and bevacizumab enhances antitumor activity against KIF5B-RET lung cancer via PI3K/AKT pathway.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although pralsetinib has shown promising efficacy in rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), acquired resistance remains a major clinical challenge and requires effective combination strategies. The study aims to explore the antitumor efficacy of the combined treatment of pralsetinib and bevacizumab in RET fusion-positive NSCLC. Methods: Ba/F3 stably expressing KIF5B-RET and subsequent pralsetinib resistant cell line were used for evaluating the antitumor efficacy Results: In this study, we demonstrated that the anti-angiogenic agent bevacizumab combined with pralsetinib can increase the sensitivity of Ba/F3 cells harboring KIF5B-RET fusion to pralsetinib through the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway. Through ELISA, we observed that the levels of VEGF were elevated when the cell line developed drug resistance. Furthermore, Conclusions: Collectively, our results suggest that the combination of pralsetinib and bevacizumab is a promising approach for treating RET fusion-positive NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.